51
|
Ceresoli G, Zucali P, Grosso F, Mencoboni M, Sauta M, Soto Parra H, Pasello G, Cortinovis D, Perrino M, Muzio A, Bruzzone A, De Vincenzo F, Degiovanni D, Bonomi M, Simonelli M, Beretta G, Giordano L, Santoro A. Vinorelbine as second or third-line therapy in pemetrexed-pretreated malignant pleural mesothelioma (MPM) patients. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv343.13] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
52
|
Bertetto O, Pacquola M, Romaniello I, Castiglione F, Bellingeri P, De Piccoli N, Fedi A, Gattino S, Finocchiaro C, Mistrangelo M, Mano M, Monagheddu C, Viale M, Ciccone G, Senore C, Giordano L. The follow-up and lifestyle (FUCSAM project). Oncology Network of Piemonte and Valle d'Aosta (ROPVdA): preliminary data. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv348.35] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
53
|
Bozzarelli S, Rimassa L, Giordano L, Garassino I, Marrari A, Tronconi M, De Sanctis R, Cavina R, Baretti M, Personeni N, Pressiani T, Santoro A. ONC-2014-001: An open-label phase II study of regorafenib in patients with metastatic solid tumors who have progressed after standard therapy - RESOUND. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv348.59] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
54
|
Zucali P, Simonelli M, De Vincenzo F, Fatuzzo G, Bertossi M, Perrino M, Miggiano C, Giordano L, Bonifacio C, Mrakic Sposta F, Santoro A. Tivantinib in combination with Carboplatin and Pemetrexed as first line treatment in patients with advanced non-squamous NSCLC or Malignant Pleural Mesothelioma: results of phase I trial. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv343.18] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
55
|
Carelli V, La Morgia C, Caporali L, Maresca A, Giordano L, Valentino M, Barboni P, Cantatore P, d'Adamo P. Genetic landscape of Leber's hereditary optic neuropathy: reflection on pathogenic mechanisms. Acta Ophthalmol 2015. [DOI: 10.1111/j.1755-3768.2015.0257] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- V. Carelli
- IRCCS Institute of Neurological Sciences of Bologna; Bellaria Hospital; Bologna Italy
- Neurology Unit; Deparment of Biomedical and Neuromotor Sciences (DIBINEM); University of Bologna; Bologna Italy
| | - C. La Morgia
- IRCCS Institute of Neurological Sciences of Bologna; Bellaria Hospital; Bologna Italy
- Neurology Unit; Deparment of Biomedical and Neuromotor Sciences (DIBINEM); University of Bologna; Bologna Italy
| | - L. Caporali
- IRCCS Institute of Neurological Sciences of Bologna; Bellaria Hospital; Bologna Italy
- Neurology Unit; Deparment of Biomedical and Neuromotor Sciences (DIBINEM); University of Bologna; Bologna Italy
| | - A. Maresca
- IRCCS Institute of Neurological Sciences of Bologna; Bellaria Hospital; Bologna Italy
- Neurology Unit; Deparment of Biomedical and Neuromotor Sciences (DIBINEM); University of Bologna; Bologna Italy
| | - L. Giordano
- Department of Biosciences, Biotechnologies and Biopharmaceutics; University of Bari; Bari Italy
| | - M.L. Valentino
- IRCCS Institute of Neurological Sciences of Bologna; Bellaria Hospital; Bologna Italy
- Neurology Unit; Deparment of Biomedical and Neuromotor Sciences (DIBINEM); University of Bologna; Bologna Italy
| | | | | | - P. d'Adamo
- IRCSS-Burlo Garofolo Children Hospital; University of Trieste; Trieste Italy
| |
Collapse
|
56
|
Smerieri M, Pal J, Savio L, Vattuone L, Ferrando R, Tosoni S, Giordano L, Pacchioni G, Rocca M. Spontaneous Oxidation of Ni Nanoclusters on MgO Monolayers Induced by Segregation of Interfacial Oxygen. J Phys Chem Lett 2015; 6:3104-3109. [PMID: 26267209 DOI: 10.1021/acs.jpclett.5b01362] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
We report the study of Ni nanoclusters deposited on MgO/Ag(100) ultrathin films (one monolayer) at T = 200 K. We show by STM analysis and DFT calculations that in the limit of low Ni coverage the formation of nanoclusters of four to six atoms occurs and that these aggregates are flat rather than 3D, as expected for Ni tetramers, pentamers, or hexamers. Both the shape of the clusters and the interatomic distance between neighboring Ni atoms are indicative that the nanoparticles do not consist of pure metal atoms but that a NiyOx structure has formed thanks to the availability of atomic oxygen accumulated at the MgO/Ag interface, with Ni clusters acting as oxygen pumps. Besides being of relevance in view of the use of metal nanoclusters in catalysis and other applications, this finding gives a further proof of the peculiar behavior of ultrathin oxide films.
Collapse
Affiliation(s)
- M Smerieri
- †IMEM-CNR, U.O.S. Genova, Via Dodecaneso 33, 16146 Genova, Italy
| | - J Pal
- †IMEM-CNR, U.O.S. Genova, Via Dodecaneso 33, 16146 Genova, Italy
- ‡Dipartimento di Fisica, Università di Genova, Via Dodecaneso 33, 16146 Genova, Italy
| | - L Savio
- †IMEM-CNR, U.O.S. Genova, Via Dodecaneso 33, 16146 Genova, Italy
| | - L Vattuone
- †IMEM-CNR, U.O.S. Genova, Via Dodecaneso 33, 16146 Genova, Italy
- ‡Dipartimento di Fisica, Università di Genova, Via Dodecaneso 33, 16146 Genova, Italy
| | - R Ferrando
- †IMEM-CNR, U.O.S. Genova, Via Dodecaneso 33, 16146 Genova, Italy
- §Dipartimento di Chimica e Chimica Industriale, Università di Genova, Via Dodecaneso 31, 16146 Genova, Italy
| | - S Tosoni
- ∥Dipartimento di Scienza dei Materiali, Università Milano Bicocca, via R. Cozzi 55, 20125 Milano, Italy
| | - L Giordano
- ∥Dipartimento di Scienza dei Materiali, Università Milano Bicocca, via R. Cozzi 55, 20125 Milano, Italy
| | - G Pacchioni
- ∥Dipartimento di Scienza dei Materiali, Università Milano Bicocca, via R. Cozzi 55, 20125 Milano, Italy
| | - M Rocca
- †IMEM-CNR, U.O.S. Genova, Via Dodecaneso 33, 16146 Genova, Italy
- ‡Dipartimento di Fisica, Università di Genova, Via Dodecaneso 33, 16146 Genova, Italy
| |
Collapse
|
57
|
Rimassa L, Bozzarelli S, Cordio S, Toppo L, Lonardi S, Zaniboni A, Bordonaro R, Liguigli W, Zagonel V, Tronconi M, Di Tommaso L, Giordano L, Santoro A. O-008 Phase II study of tivantinib (ARQ 197) in combination with Cetuximab in EGFR Inhibitor-resistant, MET-High, KRAS Wild-Type (KRASwt) Metastatic Colorectal Cancer (mCRC). Ann Oncol 2015. [DOI: 10.1093/annonc/mdv235.07] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
58
|
Castagna L, Crocchiolo R, Giordano L, Bramanti S, Carlo-Stella C, Sarina B, Chiti A, Mauro E, Gandolfi S, Todisco E, Balzarotti M, Anastasia A, Magagnoli M, Brusamolino E, Santoro A. High-dose melphalan with autologous stem cell support in refractory Hodgkin lymphoma patients as a bridge to second transplant. Bone Marrow Transplant 2015; 50:499-504. [PMID: 25621797 DOI: 10.1038/bmt.2014.304] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2014] [Revised: 10/27/2014] [Accepted: 10/31/2014] [Indexed: 11/09/2022]
Abstract
Persistence of disease after salvage therapy among relapsed or refractory Hodgkin lymphoma (HL) patients predicts poor outcome. Here, we report on 41 HL patients with active disease after salvage therapy and who received high-dose melphalan (HD-PAM) and auto-SCT as a bridge to a second autologous or an allogeneic transplantation between 2002 and 2013 at our center. Disease response was based on 18-fluoro-deoxyglucose-positron emission tomography results in all patients. Overall response rate after HD-PAM was 78% and it did not differ among PR or stable/progressive disease patients (P=1.00). Response was associated with better OS: hazard ratio=0.32 (95% confidence interval: 0.13-0.77, P=0.01) irrespective of disease status before HD-PAM. Thirty-three patients (80%) were able to complete the planned treatment, intended as tandem autologous or auto-allo transplant. Hematological and extrahematological toxicity of HD-PAM was manageable, without any treatment-related death. In conclusion, HD-PAM is a valuable therapeutic option in relapsed/refractory HL patients with active disease after salvage therapy, with an impressive 78% overall response rate and 80% rate of proceeding to further transplantation. The present data may be integrated with the growing literature on new drugs in the field of relapsed/refractory HL.
Collapse
Affiliation(s)
- L Castagna
- Department of Oncology and Hematology, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Milan, Italy
| | - R Crocchiolo
- Department of Oncology and Hematology, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Milan, Italy
| | - L Giordano
- Statistic Unit, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Milan, Italy
| | - S Bramanti
- Department of Oncology and Hematology, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Milan, Italy
| | - C Carlo-Stella
- Department of Oncology and Hematology, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Milan, Italy
| | - B Sarina
- Department of Oncology and Hematology, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Milan, Italy
| | - A Chiti
- Nuclear Medicine Department, Humanitas Clinical and Research Center, Rozzano, Milan, Italy
| | - E Mauro
- Department of Oncology and Hematology, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Milan, Italy
| | - S Gandolfi
- Department of Oncology and Hematology, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Milan, Italy
| | - E Todisco
- Department of Oncology and Hematology, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Milan, Italy
| | - M Balzarotti
- Department of Oncology and Hematology, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Milan, Italy
| | - A Anastasia
- Department of Oncology and Hematology, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Milan, Italy
| | - M Magagnoli
- Department of Oncology and Hematology, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Milan, Italy
| | - E Brusamolino
- Department of Oncology and Hematology, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Milan, Italy
| | - A Santoro
- Department of Oncology and Hematology, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Milan, Italy
| |
Collapse
|
59
|
Viggiano E, Marabotti A, Burlina AP, Cazzorla C, D'Apice MR, Giordano L, Fasan I, Novelli G, Facchiano A, Burlina AB. Clinical and molecular spectra in galactosemic patients from neonatal screening in northeastern Italy: structural and functional characterization of new variations in the galactose-1-phosphate uridyltransferase (GALT) gene. Gene 2015; 559:112-8. [PMID: 25592817 DOI: 10.1016/j.gene.2015.01.013] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2014] [Revised: 12/29/2014] [Accepted: 01/08/2015] [Indexed: 10/24/2022]
Abstract
Classical galactosemia is an autosomal recessive inborn error of metabolism due to mutations of the GALT gene leading to toxic accumulation of galactose and derived metabolites. With the benefit of early diagnosis by neonatal screening and early therapy, the acute presentation of classical galactosemia can be prevented. However, despite early diagnosis and treatment, the long term outcome for these patients is still unpredictable because they may go on to develop cognitive disability, speech problems, neurological and/or movement disorders and, in females, ovarian dysfunction. The objectives of the current study were to report our experience with a group of galactosemic patients identified through the neonatal screening programs in northeastern Italy during the last 30years. No neonatal deaths due to galactosemia complications occurred after the introduction of the neonatal screening program. However, despite the early diagnosis and dietary treatment, the patients with classical galactosemia showed one or more long-term complications. A total of 18 different variations in the GALT gene were found in the patient cohort: 12 missense, 2 frameshift, 1 nonsense, 1 deletion, 1 silent variation, and 1 intronic. Six (p.R33P, p.G83V, p.P244S, p.L267R, p.L267V, p.E271D) were new variations. The most common variation was p.Q188R (12 alleles, 31.5%), followed by p.K285N (6 alleles, 15.7%) and p.N314D (6 alleles, 15.7%). The other variations comprised 1 or 2 alleles. In the patients carrying a new mutation, the biochemical analysis of GALT activity in erythrocytes showed an activity of <1%. In silico analysis (SIFT, PolyPhen-2 and the computational analysis on the static protein structure) showed potentially damaging effects of the six new variations on the GALT protein, thus expanding the genetic spectrum of GALT variations in Italy. The study emphasizes the difficulty in establishing a genotype-phenotype correlation in classical galactosemia and underlines the importance of molecular diagnostic testing prior to making any treatment.
Collapse
Affiliation(s)
- E Viggiano
- Division of Inborn Metabolic Diseases, Department of Paediatrics, University Hospital of Padova, Italy
| | - A Marabotti
- Department of Chemistry and Biology, University of Salerno, via Giovanni Paolo II 132, 84084 Fisciano, SA, Italy
| | - A P Burlina
- Neurological Unit, St. Bassiano Hospital, Bassano del Grappa, Consultant in Neurometabolic Hereditary Diseases at the University Hospital of Padova, Italy
| | - C Cazzorla
- Division of Inborn Metabolic Diseases, Department of Paediatrics, University Hospital of Padova, Italy
| | - M R D'Apice
- Department of Biomedicine and Prevention, School of Medicine, University of Rome "Tor Vergata" and Fondazione PTV "Policlinico Tor Vergata", Rome, Italy
| | - L Giordano
- Division of Inborn Metabolic Diseases, Department of Paediatrics, University Hospital of Padova, Italy
| | - I Fasan
- Division of Inborn Metabolic Diseases, Department of Paediatrics, University Hospital of Padova, Italy
| | - G Novelli
- Department of Biomedicine and Prevention, School of Medicine, University of Rome "Tor Vergata" and Fondazione PTV "Policlinico Tor Vergata", Rome, Italy
| | - A Facchiano
- National Research Council, Institute of Food Science, via Roma 64, 83100 Avellino, Italy
| | - A B Burlina
- Division of Inborn Metabolic Diseases, Department of Paediatrics, University Hospital of Padova, Italy.
| |
Collapse
|
60
|
Castagna L, Bramanti S, Furst S, Giordano L, Crocchiolo R, Sarina B, Mauro E, Morabito L, Bouabdallah R, Coso D, Balzarotti M, Broussais F, El-Cheikh J, Stella CC, Brusamolino E, Blaise D, Santoro A. Erratum: Nonmyeloablative conditioning, unmanipulated haploidentical SCT and post-infusion CY for advanced lymphomas. Bone Marrow Transplant 2014. [DOI: 10.1038/bmt.2014.267] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
61
|
Ceresoli GL, Grosso F, Zucali PA, Mencoboni M, Pasello G, Ripa C, Degiovanni D, Simonelli M, Bruzzone A, Dipietrantonj C, Piccolini E, Beretta GD, Favaretto AG, Giordano L, Santoro A, Botta M. Prognostic factors in elderly patients with malignant pleural mesothelioma: results of a multicenter survey. Br J Cancer 2014; 111:220-6. [PMID: 24918816 PMCID: PMC4102949 DOI: 10.1038/bjc.2014.312] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2014] [Revised: 04/29/2014] [Accepted: 05/12/2014] [Indexed: 12/15/2022] Open
Abstract
BACKGROUND The incidence of malignant pleural mesothelioma (MPM) in elderly patients is increasing. There are no specific guidelines for their management. METHODS The clinical records of elderly patients (⩾70 years old) with MPM referred from January 2005 to November 2011 to six Italian Centres were reviewed. Age, gender, histology, International Mesothelioma Interest Group (IMIG) stage, Eastern Cooperative Oncology Group Performance Status (ECOG-PS), Charlson Comorbidity Index (CCI) and treatment modalities were analysed and correlated to overall survival (OS). RESULTS In total, 241 patients were identified. Charlson Comorbidity Index was ⩾1 in 92 patients (38%). Treatment was multimodality therapy including surgery in 18, chemotherapy alone in 180 (75%) and best supportive care in 43 cases (18%). Chemotherapy was mainly pemetrexed based. Median OS was 11.4 months. Non-epithelioid histology (HR 2.32; 95% CI 1.66-3.23, P<0.001), age ⩾75 years (HR 1.44; 95% CI 1.08-1.93, P=0.014), advanced (III-IV) stage (HR 1.47; 95% CI 1.09-1.98, P=0.011) and CCI⩾1 (HR 1.38; 95% CI 1.02-1.85, P=0.034) were associated to a shorter OS. Treatment with pemetrexed was associated with improved OS (HR 0.40; 95% CI 0.28-0.56, P<0.001). CONCLUSIONS Non-epithelioid histology, age ⩾75 years, advanced IMIG stage and presence of comorbidities according to CCI were significant prognostic factors in elderly patients with MPM. Treatment with pemetrexed-based chemotherapy was feasible in this setting. Prospective dedicated trials in MPM elderly patients selected according to prognostic factors including comorbidity scales are warranted.
Collapse
Affiliation(s)
- G L Ceresoli
- Oncology, Cliniche Humanitas Gavazzeni, Bergamo, Italy
| | - F Grosso
- Oncology, Ospedale SS Antonio e Biagio, Alessandria, Italy
| | - P A Zucali
- Oncology, Humanitas Cancer Center, Rozzano (Milan), Italy
| | - M Mencoboni
- Oncology, Ospedale Villa Scassi, Sampierdarena, Genova, Italy
| | - G Pasello
- Oncology, Istituto Oncologico Veneto, Padova, Italy
| | - C Ripa
- Oncology, Cliniche Humanitas Gavazzeni, Bergamo, Italy
| | - D Degiovanni
- Palliative Care Unit, Ospedale S. Spirito, Casale Monferrato, Italy
| | - M Simonelli
- Oncology, Humanitas Cancer Center, Rozzano (Milan), Italy
| | - A Bruzzone
- Oncology, Ospedale Villa Scassi, Sampierdarena, Genova, Italy
| | | | - E Piccolini
- Pneumology, Ospedale S. Spirito, Casale Monferrato, Italy
| | - G D Beretta
- Oncology, Cliniche Humanitas Gavazzeni, Bergamo, Italy
| | | | - L Giordano
- Biostatistic Unit, Humanitas Cancer Center, Rozzano (Milan), Italy
| | - A Santoro
- Oncology, Humanitas Cancer Center, Rozzano (Milan), Italy
| | - M Botta
- Oncology, Ospedale S. Spirito, Casale Monferrato, Italy
| |
Collapse
|
62
|
Colombaro V, Decleves AE, Voisin V, Giordano L, Jadot I, Habsch I, Flamion B, Caron N, Ngo JP, Kett M, Pearson J, Smith D, Abdelkader A, Kar S, Bertram J, Gardiner B, Evans R, Emans TW, Ow CP, Joles JA, Evans RG, Malpas SC, Koeners MP, Dube GR, Campos-Bilderback SB, Sandoval RM, Bosukonda D, Keck P, Leger R, Bey P, Carlson W, Molitoris BA, Cernaro V, Sfacteria A, Lucisano S, Lupica R, Bruzzese AM, Aloisi C, Montuori F, Lorenzano G, Visconti L, Buemi M. EXPERIMENTAL ISCHEMIA. Nephrol Dial Transplant 2014. [DOI: 10.1093/ndt/gfu135] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
63
|
Soleimani M, Barone S, Xu J, Zahedi K, Pavlov T, Levchenko V, Ilatovskaya D, Palygin O, Staruschenko A, Lee CT, Ng HY, Lee YT, Lien YH, Lai LW, Chiou T, Fischereder M, Michalke B, Schmoeckel E, Habicht A, Szabados B, Nelson PJ, Stangl M, Colombaro V, Decleves AE, Jadot I, Voisin V, Giordano L, Habsch I, Flamion B, Caron N. WATER AND SALT. Nephrol Dial Transplant 2014. [DOI: 10.1093/ndt/gfu113] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
64
|
Gillanders F, Giordano L, Díaz SA, Jovin TM, Jares-Erijman EA. Photoswitchable fluorescent diheteroarylethenes: substituent effects on photochromic and solvatochromic properties. Photochem Photobiol Sci 2014; 13:603-12. [PMID: 24496436 DOI: 10.1039/c3pp50374g] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
Abstract
Photoswitchable fluorescent diheteroarylethenes are promising candidates for applications in super-resolution molecular localization fluorescence microscopy thanks to their high quantum yields and fatigue-resistant photoswitching characteristics. We have studied the effect of varying substituents on the photophysical properties of six sulfone derivatives of diheteroarylethenes, which display fluorescence in one (closed form) of two thermally stable photochromic states. Electron-donating substituents displace the absorption and emission spectra towards the red without substantially affecting the fluorescence quantum yields. Furthermore, ethoxybromo, a very electron-donating substituent, stabilizes the excited state of the closed isomer to the extent of almost entirely inhibiting its cycloreversion. Multi-parameter Hammett correlations indicate a relationship between the emission maxima and electron-donating character, providing a useful tool in the design of future photochromic molecules. Most of the synthesized compounds exhibit small bathochromic shifts and shorter fluorescence lifetimes with an increase in solvent polarity. However, the ethoxybromo-substituted fluorescent photochrome is unique in its strong solvatochromic behaviour, constituting a photoactivatable (photochromic), fluorescent and highly solvatochromic small organic compound. The Catalán formalism identified solvent dipolarity as the principal basis of the solvatochromism, reflecting the highly polarized nature of this molecule.
Collapse
Affiliation(s)
- Florencia Gillanders
- Laboratory of Cellular Dynamics, Max Planck Institute for Biophysical Chemistry, Am Fassberg 11, 37077 Göttingen, Germany.
| | | | | | | | | |
Collapse
|
65
|
Li Z, Chen HYT, Schouteden K, Lauwaet K, Giordano L, Trioni MI, Janssens E, Iancu V, Van Haesendonck C, Lievens P, Pacchioni G. Self-doping of ultrathin insulating films by transition metal atoms. Phys Rev Lett 2014; 112:026102. [PMID: 24484029 DOI: 10.1103/physrevlett.112.026102] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/18/2013] [Indexed: 06/03/2023]
Abstract
Single magnetic Co atoms are deposited on atomically thin NaCl films on Au(111). Two different adsorption sites are revealed by high-resolution scanning tunneling microscopy (STM), i.e., at Na and at Cl locations. Using density functional based simulations of the STM images, we show that the Co atoms substitute with either a Na or Cl atom of the NaCl surface, resulting in cationic and anionic Co dopants with a high thermal stability. The dependence of the magnetic coupling between neighboring Co atoms on their separation is investigated via spatially resolved measurement of the local density of states.
Collapse
Affiliation(s)
- Z Li
- Laboratory of Solid-State Physics and Magnetism, KU Leuven, BE-3001 Leuven, Belgium
| | - H-Y T Chen
- Dipartimento di Scienza dei Materiali, Università di Milano-Bicocca, Via Cozzi 53, I-20125 Milano, Italy
| | - K Schouteden
- Laboratory of Solid-State Physics and Magnetism, KU Leuven, BE-3001 Leuven, Belgium
| | - K Lauwaet
- Laboratory of Solid-State Physics and Magnetism, KU Leuven, BE-3001 Leuven, Belgium
| | - L Giordano
- Dipartimento di Scienza dei Materiali, Università di Milano-Bicocca, Via Cozzi 53, I-20125 Milano, Italy
| | - M I Trioni
- CNR-National Research Council of Italy, ISTM, Via Golgi 19, I-20133 Milano, Italy
| | - E Janssens
- Laboratory of Solid-State Physics and Magnetism, KU Leuven, BE-3001 Leuven, Belgium
| | - V Iancu
- Laboratory of Solid-State Physics and Magnetism, KU Leuven, BE-3001 Leuven, Belgium
| | - C Van Haesendonck
- Laboratory of Solid-State Physics and Magnetism, KU Leuven, BE-3001 Leuven, Belgium
| | - P Lievens
- Laboratory of Solid-State Physics and Magnetism, KU Leuven, BE-3001 Leuven, Belgium
| | - G Pacchioni
- Dipartimento di Scienza dei Materiali, Università di Milano-Bicocca, Via Cozzi 53, I-20125 Milano, Italy
| |
Collapse
|
66
|
Nicosia F, Giordano L, Bonini L, Corda L, Bolzon M, Bettinzoli M, Braghini A, Accorsi P, Tantucci C. Hyperventilation and seizures in an adolescent female. Monaldi Arch Chest Dis 2013; 79:93-5. [PMID: 24354099 DOI: 10.4081/monaldi.2013.99] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
A 16 year-old girl was admitted after suffering from recurrent episodes of dyspnea and stridor, cyanosis, loss of contact, stiffening of all four limbs, clenching of the jaw and eye retroversion that lasted for a few seconds to a minute, followed by slow recovery of consciousness without any loss of sphincter control. These symptoms began at the age of 11 and worsened over time. Prolonged rate corrected QT intervals was observed with an ECG. Two cardio-respiratory monitorings were performed (one during daytime hours while the patient was awake, and one at night time while the patient slept). Daytime recordings showed 17 central apnoeas and 97 central hypopneas, with an apnea-hypopnea index (AHI) of 13.2 events/hour, that were associated with severe oxyhemoglobin desaturation. In contrast, night time recordings were normal (AHI=1.1 events/hour). The patient underwent diurnal monitoring of transcutaneous pCO2(PtcCO2), transcutaneous O2(PtcO2), SpO2 and end tidal CO2 (PETCO2), with simultaneous monitoring of regional cerebral oxymetry (rSO2) which showed values of PtcCO2 between 8 and 15 mmHg, suggesting several episodes of marked hyperventilation. Twenty-nine episodes of severe arterial desaturation (SpO2<50%) were registered, all after the same number of apnea events, with ascent of PtcO2 up to 28 mmHg at the end of apnea. During the final phase of apnea, the patient showed cyanosis, contact disturbance, grimaces, oral movements of rhyme, and, on three occasions, partial seizures. A mask was packaged and applied daytime to the face of the patient during episodes of hyperventilation to prevent, together with a psychiatric follow up, rapid falls of PaCO2 levels determining central apnoeas.
Collapse
Affiliation(s)
- F Nicosia
- Cattedra di Geriatria, Università di Brescia
| | - L Giordano
- Servizio di Neuropsichiatria Infantile, Ospedale dei Bambini, Brescia
| | - L Bonini
- Servizio di Neuropsichiatria Infantile, Ospedale dei Bambini, Brescia
| | - L Corda
- Prima Medicina Interna, Spedali Civili, Brescia
| | - M Bolzon
- Servizio di Neuroanestesia e Neurorianimazione, Ospedale Niguarda Cà Granda, Milano
| | - M Bettinzoli
- Cattedra di Malattie dell'Apparato Respiratorio, Università di Brescia, Italy
| | - A Braghini
- Cattedra di Malattie dell'Apparato Respiratorio, Università di Brescia, Italy
| | - P Accorsi
- Servizio di Neuropsichiatria Infantile, Ospedale dei Bambini, Brescia
| | - C Tantucci
- Cattedra di Malattie dell'Apparato Respiratorio, Università di Brescia, Italy
| |
Collapse
|
67
|
Zucali PA, Perrino M, Lorenzi E, Ceresoli GL, De Vincenzo F, Simonelli M, Gianoncelli L, De Sanctis R, Giordano L, Santoro A. Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma. Lung Cancer 2013; 84:265-70. [PMID: 24321581 DOI: 10.1016/j.lungcan.2013.11.011] [Citation(s) in RCA: 40] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2013] [Revised: 11/02/2013] [Accepted: 11/11/2013] [Indexed: 02/07/2023]
Abstract
BACKGROUND Pemetrexed-platinum chemotherapy is the standard first-line treatment of unresectable malignant pleural mesothelioma (MPM). At progression, patients are generally selected to experimental trials, when available, or, in every-day clinical practice, they are offered second-line chemotherapy. The optimal treatment has not yet been defined. The aim of this retrospective, single-center study was to evaluate the activity and toxicity of vinorelbine administered to a consecutive series of pemetrexed-pretreated MPM patients. METHODS Vinorelbine 25 mg/m(2) was administered intravenously as a single agent on days 1, 8 every three weeks, either as second-line (2L) or further-line (>2L) therapy. Treatment was repeated for a maximum of 6 cycles, until progression, or unacceptable toxicity. RESULTS Fifty-nine patients were included in this analysis. Vinorelbine was given to 34 patients as 2L, and to 25 as > 2L treatment. The median age was 69 years (range 45-80). Forty-two patients (71.2%) had a good EORTC prognostic score. Partial response was observed in 9 (15.2%) cases, stable disease in 20 (33.9%). The overall disease control rate (DCR) was 49.1%. Median progression-free survival (PFS) and overall survival (OS) were 2.3 and 6.2 months, respectively. ECOG performance status (PS) (HR(0 vs. 1-2) 0.50; 95%CI: 0.3-0.8; p = 0.014) and PFS ≥ 6 months following first-line (FL) chemotherapy (HR(FL-PFS>6 ms vs. <6 ms) 0.50; 95%CI: 0.3-0.9; p = 0.031) were significantly associated to OS in multivariate analysis. No difference was observed in terms of DCR, PFS, and OS in relation to age, histology, sex, line of vinorelbine therapy, or response to FL treatment. Hematological toxicity was acceptable, with grade 3/4 neutropenia occurring in 5 (8.4%) patients, and there were no cases of febrile neutropenia. The main non-hematological toxicities were grade 2 fatigue in 17 (28.8%) and constipation in 7 (11.8%) patients. CONCLUSIONS Vinorelbine was moderately active in pemetrexed-pretreated MPM patients, with an acceptable toxicity profile, particularly in patients with ECOG-PS0 and FL-PFS ≥ 6 months.
Collapse
Affiliation(s)
- P A Zucali
- Department of Medical Oncology and Hematology, Humanitas Clinical and Research Center, Rozzano, Milan, Italy.
| | - M Perrino
- Department of Medical Oncology and Hematology, Humanitas Clinical and Research Center, Rozzano, Milan, Italy
| | - E Lorenzi
- Department of Medical Oncology and Hematology, Humanitas Clinical and Research Center, Rozzano, Milan, Italy
| | - G L Ceresoli
- Department of Medical Oncology and Hematology, Istituto Humanitas Gavazzeni, Bergamo, Italy
| | - F De Vincenzo
- Department of Medical Oncology and Hematology, Humanitas Clinical and Research Center, Rozzano, Milan, Italy
| | - M Simonelli
- Department of Medical Oncology and Hematology, Humanitas Clinical and Research Center, Rozzano, Milan, Italy
| | - L Gianoncelli
- Department of Medical Oncology and Hematology, Humanitas Clinical and Research Center, Rozzano, Milan, Italy
| | - R De Sanctis
- Department of Medical Oncology and Hematology, Humanitas Clinical and Research Center, Rozzano, Milan, Italy
| | - L Giordano
- Biostatistic Unit, Humanitas Clinical and Research Center, Rozzano, Milan, Italy
| | - A Santoro
- Department of Medical Oncology and Hematology, Humanitas Clinical and Research Center, Rozzano, Milan, Italy
| |
Collapse
|
68
|
Ceresoli GL, Zucali PA, Mencoboni M, Botta M, Grossi F, Cortinovis D, Zilembo N, Ripa C, Tiseo M, Favaretto AG, Soto-Parra H, De Vincenzo F, Bruzzone A, Lorenzi E, Gianoncelli L, Ercoli B, Giordano L, Santoro A. Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma. Br J Cancer 2013; 109:552-8. [PMID: 23860535 PMCID: PMC3738125 DOI: 10.1038/bjc.2013.368] [Citation(s) in RCA: 78] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2013] [Revised: 06/10/2013] [Accepted: 06/22/2013] [Indexed: 12/21/2022] Open
Abstract
Background: The aim of this open label phase II study (NCT00407459) was to assess the activity of the vascular endothelial growth factor (VEGF) inhibitor bevacizumab combined with pemetrexed and carboplatin in patients with previously untreated, unresectable malignant pleural mesothelioma (MPM). Methods: Eligible patients received pemetrexed 500 mg m−2, carboplatin area under the plasma concentration–time curve (AUC) 5 mg ml−1 per minute and bevacizumab 15 mg kg−1, administered intravenously every 21 days for six cycles, followed by maintenance bevacizumab. The primary end point of the study was progression-free survival (PFS). A 50% improvement in median PFS in comparison with standard pemetrexed/platinum combinations (from 6 to 9 months) was postulated. Results: Seventy-six patients were evaluable for analysis. A partial response was achieved in 26 cases (34.2%, 95% CI 23.7–46.0%). Forty-four (57.9%, 95% CI 46.0–69.1%) had stable disease. Median PFS and overall survival were 6.9 and 15.3 months, respectively. Haematological and non-haematological toxicities were generally mild; however, some severe adverse events were reported, including grade 3–4 fatigue in 8% and bowel perforation in 4% of patients. Three toxic deaths occurred. Conclusion: The primary end point of the trial was not reached. However, due to the limitation of a non-randomised phase II design, further data are needed before drawing any definite conclusion on the role of bevacizumab in MPM.
Collapse
Affiliation(s)
- G L Ceresoli
- Department of Medical Oncology, Cliniche Humanitas Gavazzeni, Bergamo, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
69
|
Santoro A, Comandone A, Basso U, Soto Parra H, De Sanctis R, Stroppa E, Marcon I, Giordano L, Lutman F, Boglione A, Bertuzzi A. Phase II prospective study with sorafenib in advanced soft tissue sarcomas after anthracycline-based therapy. Ann Oncol 2013; 24:1093-1098. [DOI: 10.1093/annonc/mds607] [Citation(s) in RCA: 45] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/30/2023] Open
|
70
|
Giudice J, Barcos LS, Guaimas FF, Penas-Steinhardt A, Giordano L, Jares-Erijman EA, Coluccio Leskow F. Insulin and insulin like growth factor II endocytosis and signaling via insulin receptor B. Cell Commun Signal 2013; 11:18. [PMID: 23497114 PMCID: PMC3607927 DOI: 10.1186/1478-811x-11-18] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2012] [Accepted: 12/14/2012] [Indexed: 12/12/2022] Open
Abstract
Background Insulin and insulin-like growth factors (IGFs) act on tetrameric tyrosine kinase receptors controlling essential functions including growth, metabolism, reproduction and longevity. The insulin receptor (IR) binds insulin and IGFs with different affinities triggering different cell responses. Results We showed that IGF-II induces cell proliferation and gene transcription when IR-B is over-expressed. We combined biotinylated ligands with streptavidin conjugated quantum dots and visible fluorescent proteins to visualize the binding of IGF-II and insulin to IR-B and their ensuing internalization. By confocal microscopy and flow cytometry in living cells, we studied the internalization kinetic through the IR-B of both IGF-II, known to elicit proliferative responses, and insulin, a regulator of metabolism. Conclusions IGF-II promotes a faster internalization of IR-B than insulin. We propose that IGF-II differentially activates mitogenic responses through endosomes, while insulin-activated IR-B remains at the plasma membrane. This fact could facilitate the interaction with key effector molecules involved in metabolism regulation.
Collapse
Affiliation(s)
- Jimena Giudice
- Departamento de Química Biológica, Facultad de Ciencias Exactas y Naturales (FCEN), Universidad de Buenos Aires (UBA), IQUIBICEN, CONICET, Buenos Aires, Argentina.
| | | | | | | | | | | | | |
Collapse
|
71
|
Díaz SA, Giordano L, Azcárate JC, Jovin TM, Jares-Erijman EA. Quantum Dots as Templates for Self-Assembly of Photoswitchable Polymers: Small, Dual-Color Nanoparticles Capable of Facile Photomodulation. J Am Chem Soc 2013; 135:3208-17. [DOI: 10.1021/ja3117813] [Citation(s) in RCA: 70] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Sebastián A. Díaz
- Laboratory of Cellular Dynamics, Max Planck Institute for Biophysical Chemistry, Am
Fassberg 11, 37077 Göttingen, Germany
- Departamento de Química
Orgánica, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, CIHIDECAR, CONICET, 1428
Buenos Aires, Argentina
| | - Luciana Giordano
- Laboratory of Cellular Dynamics, Max Planck Institute for Biophysical Chemistry, Am
Fassberg 11, 37077 Göttingen, Germany
| | - Julio C. Azcárate
- Instituto
de Investigaciones Fisicoquímicas
Teóricas y Aplicadas, Facultad de Ciencias Exactas, Universidad Nacional de La Plata, CONICET, La Plata,
Argentina
| | - Thomas M. Jovin
- Laboratory of Cellular Dynamics, Max Planck Institute for Biophysical Chemistry, Am
Fassberg 11, 37077 Göttingen, Germany
| | - Elizabeth A. Jares-Erijman
- Departamento de Química
Orgánica, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, CIHIDECAR, CONICET, 1428
Buenos Aires, Argentina
| |
Collapse
|
72
|
Pressiani T, Boni C, Rimassa L, Labianca R, Fagiuoli S, Salvagni S, Ferrari D, Cortesi E, Porta C, Mucciarini C, Latini L, Carnaghi C, Banzi M, Fanello S, De Giorgio M, Lutman FR, Torzilli G, Tommasini MA, Ceriani R, Covini G, Tronconi MC, Giordano L, Locopo N, Naimo S, Santoro A. Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis. Ann Oncol 2013; 24:406-411. [PMID: 23041587 DOI: 10.1093/annonc/mds343] [Citation(s) in RCA: 117] [Impact Index Per Article: 10.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open
Abstract
BACKGROUND Sorafenib has shown survival benefits in patients with advanced hepatocellular carcinoma (HCC) and Child-Pugh (CP) class A liver function. There are few prospective data on sorafenib in patients with HCC and CP class B. PATIENTS AND METHODS A consecutive prospective series of 300 patients with CP class A or B HCC were enrolled in a dual-phase trial to determine survival and safety data according to liver function (class A or B) in patients receiving oral sorafenib 800 mg daily. [Results of this study were presented in part at the ASCO 2012 Gastrointestinal Cancers Symposium, 19-21 January 2012. J Clin Oncol 2012; 30 (Suppl 4): abstract 306.] RESULTS Overall progression-free survival (PFS), time to progression (TTP) and overall survival (OS) were 3.9, 4.1 and 9.1 months, respectively. For patients with CP class A versus B status, PFS was 4.3 versus 2.1 months, TTP was 4.2 versus 3.8 months and OS was 10.0 versus 3. 8 months. Extrahepatic spread was associated with worse outcomes but taken together with CP class, liver function played a greater role in reducing survival. Adverse events for the two CP groups were similar. CONCLUSION Although patients with HCC and CP class B liver function have poorer outcomes than those with CP class A function, data suggest that patients with CP class B liver function can tolerate treatment and may still benefit from sorafenib.
Collapse
Affiliation(s)
- T Pressiani
- Medical Oncology and Haematology Unit, Humanitas Cancer Center, Istituto Clinico Humanitas, IRCCS, Rozzano
| | - C Boni
- Medical Oncology, Arcispedale Santa Maria Nuova, IRCCS, Reggio Emilia
| | - L Rimassa
- Medical Oncology and Haematology Unit, Humanitas Cancer Center, Istituto Clinico Humanitas, IRCCS, Rozzano.
| | - R Labianca
- Department of Oncology and Hematology, Ospedali Riuniti di Bergamo, Bergamo
| | - S Fagiuoli
- Division of Gastroenterology and Transplant Hepatology, Department of Medicine, Ospedali Riuniti di Bergamo, Bergamo
| | - S Salvagni
- Oncology Division, Azienda Ospedaliero-Universitaria, Parma
| | - D Ferrari
- Department of Oncology, San Paolo University Hospital, Milano
| | - E Cortesi
- Department of Radiology, Oncology and Human Patology, Sapienza - University of Rome, Roma
| | - C Porta
- Medical Oncology, IRCCS San Matteo University Hospital Foundation, Pavia
| | - C Mucciarini
- Oncology Department, "Ramazzini" Hospital - Carpi
| | - L Latini
- Medical Oncology, Hospital of Macerata, Macerata
| | - C Carnaghi
- Medical Oncology and Haematology Unit, Humanitas Cancer Center, Istituto Clinico Humanitas, IRCCS, Rozzano
| | - M Banzi
- Medical Oncology, Arcispedale Santa Maria Nuova, IRCCS, Reggio Emilia
| | - S Fanello
- Medical Oncology, Arcispedale Santa Maria Nuova, IRCCS, Reggio Emilia
| | - M De Giorgio
- Division of Gastroenterology and Transplant Hepatology, Department of Medicine, Ospedali Riuniti di Bergamo, Bergamo
| | - F R Lutman
- Department of Radiology, Humanitas Cancer Center, Istituto Clinico Humanitas, IRCCS, Rozzano
| | - G Torzilli
- University of Milan - School of Medicine, Liver Surgery Unit, Humanitas Cancer Center, Istituto Clinico Humanitas, IRCCS, Rozzano
| | - M A Tommasini
- Department of Gastroenterology, Liver Unit, Istituto Clinico Humanitas, IRCCS, Rozzano
| | - R Ceriani
- Department of Gastroenterology, Liver Unit, Istituto Clinico Humanitas, IRCCS, Rozzano
| | - G Covini
- Department of Gastroenterology, Liver Unit, Istituto Clinico Humanitas, IRCCS, Rozzano
| | - M C Tronconi
- Medical Oncology and Haematology Unit, Humanitas Cancer Center, Istituto Clinico Humanitas, IRCCS, Rozzano
| | - L Giordano
- Biostatistic Unit, Humanitas Cancer Center, Istituto Clinico Humanitas, IRCCS, Rozzano, Italy
| | - N Locopo
- Medical Oncology and Haematology Unit, Humanitas Cancer Center, Istituto Clinico Humanitas, IRCCS, Rozzano
| | - S Naimo
- Medical Oncology and Haematology Unit, Humanitas Cancer Center, Istituto Clinico Humanitas, IRCCS, Rozzano
| | - A Santoro
- Medical Oncology and Haematology Unit, Humanitas Cancer Center, Istituto Clinico Humanitas, IRCCS, Rozzano
| |
Collapse
|
73
|
von Karsa L, Patnick J, Segnan N, Atkin W, Halloran S, Lansdorp-Vogelaar I, Malila N, Minozzi S, Moss S, Quirke P, Steele RJ, Vieth M, Aabakken L, Altenhofen L, Ancelle-Park R, Antoljak N, Anttila A, Armaroli P, Arrossi S, Austoker J, Banzi R, Bellisario C, Blom J, Brenner H, Bretthauer M, Camargo Cancela M, Costamagna G, Cuzick J, Dai M, Daniel J, Dekker E, Delicata N, Ducarroz S, Erfkamp H, Espinàs JA, Faivre J, Faulds Wood L, Flugelman A, Frkovic-Grazio S, Geller B, Giordano L, Grazzini G, Green J, Hamashima C, Herrmann C, Hewitson P, Hoff G, Holten I, Jover R, Kaminski MF, Kuipers EJ, Kurtinaitis J, Lambert R, Launoy G, Lee W, Leicester R, Leja M, Lieberman D, Lignini T, Lucas E, Lynge E, Mádai S, Marinho J, Maučec Zakotnik J, Minoli G, Monk C, Morais A, Muwonge R, Nadel M, Neamtiu L, Peris Tuser M, Pignone M, Pox C, Primic-Zakelj M, Psaila J, Rabeneck L, Ransohoff D, Rasmussen M, Regula J, Ren J, Rennert G, Rey J, Riddell RH, Risio M, Rodrigues V, Saito H, Sauvaget C, Scharpantgen A, Schmiegel W, Senore C, Siddiqi M, Sighoko D, Smith R, Smith S, Suchanek S, Suonio E, Tong W, Törnberg S, Van Cutsem E, Vignatelli L, Villain P, Voti L, Watanabe H, Watson J, Winawer S, Young G, Zaksas V, Zappa M, Valori R. European guidelines for quality assurance in colorectal cancer screening and diagnosis: overview and introduction to the full supplement publication. Endoscopy 2013; 45:51-9. [PMID: 23212726 PMCID: PMC4482205 DOI: 10.1055/s-0032-1325997] [Citation(s) in RCA: 186] [Impact Index Per Article: 16.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
Population-based screening for early detection and treatment of colorectal cancer (CRC) and precursor lesions, using evidence-based methods, can be effective in populations with a significant burden of the disease provided the services are of high quality. Multidisciplinary, evidence-based guidelines for quality assurance in CRC screening and diagnosis have been developed by experts in a project co-financed by the European Union. The 450-page guidelines were published in book format by the European Commission in 2010. They include 10 chapters and over 250 recommendations, individually graded according to the strength of the recommendation and the supporting evidence. Adoption of the recommendations can improve and maintain the quality and effectiveness of an entire screening process, including identification and invitation of the target population, diagnosis and management of the disease and appropriate surveillance in people with detected lesions. To make the principles, recommendations and standards in the guidelines known to a wider professional and scientific community and to facilitate their use in the scientific literature, the original content is presented in journal format in an open-access Supplement of Endoscopy. The editors have prepared the present overview to inform readers of the comprehensive scope and content of the guidelines.
Collapse
Affiliation(s)
| | - L. von Karsa
- International Agency for Research on Cancer, Lyon, France
| | - J. Patnick
- NHS Cancer Screening Programmes Sheffield, United Kingdom,Oxford University Cancer Screening Research Unit, Cancer Epidemiology Unit, University of Oxford, Oxford, United Kingdom
| | - N. Segnan
- International Agency for Research on Cancer, Lyon, France,CPO Piemonte, AO Città della Salute e della Scienza di Torino, Turin Italy
| | - W. Atkin
- Imperial College London, London, United Kingdom
| | - S. Halloran
- Bowel Cancer Screening Southern Programme Hub, Royal Surrey County Hospital NHS Foundation Trust, Guildford, United Kingdom,University of Surrey, Guildford, United Kingdom
| | | | - N. Malila
- Finnish Cancer Registry, Helsinki, Finland
| | - S. Minozzi
- CPO Piemonte, AO Città della Salute e della Scienza di Torino, Turin Italy
| | - S. Moss
- The Institute of Cancer Research, Royal Cancer Hospital, Sutton, United Kingdom
| | - P. Quirke
- Leeds Institute of Molecular Medicine, St James’ University Hospital, Leeds, United Kingdom
| | - R. J. Steele
- Ninewells Hospital and Medical School, Dundee, United Kingdom
| | - M. Vieth
- Institute of Pathology, Klinikum Bayreuth, Bayreuth, Germany
| | - L. Aabakken
- Department of Medical Gastroenterology, Stavanger University Hospital, Stavanger, Norway
| | - L. Altenhofen
- Central Research Institute of Ambulatory Health Care, Berlin, Germany
| | | | - N. Antoljak
- Croatian National Institute of Public Health, Zagreb, Croatia,University of Zagreb School of Medicine, Zagreb, Croatia
| | - A. Anttila
- Finnish Cancer Registry, Helsinki, Finland
| | - P. Armaroli
- CPO Piemonte, AO Città della Salute e della Scienza di Torino, Turin Italy
| | | | - J. Austoker
- University of Oxford, Oxford, United Kingdom
| | - R. Banzi
- Mario Negri Institute for Pharmacological Research, Milan, Italy
| | - C. Bellisario
- CPO Piemonte, AO Città della Salute e della Scienza di Torino, Turin Italy
| | - J. Blom
- Karolinska Institutet, Stockholm, Sweden
| | - H. Brenner
- German Cancer Research Center, Heidelberg, Germany
| | - M. Bretthauer
- Institute of Health and Society, University of Oslo, Oslo, Norway
| | - M. Camargo Cancela
- National Cancer Registry, Cork, Ireland,Formerly International Agency for Research on Cancer, Lyon, France
| | | | - J. Cuzick
- Wolfson Institute of Preventive Medicine, Queen Mary University of London, United Kingdom
| | - M. Dai
- Cancer Institute & Hospital, Chinese Academy of Medical Sciences, Beijing, China
| | - J. Daniel
- Formerly International Agency for Research on Cancer, Lyon, France,American Cancer Society, Atlanta, Georgia, United States of America
| | - E. Dekker
- Academic Medical Centre, Amsterdam, the Netherlands
| | - N. Delicata
- National Health Screening Services, Ministry of Health, Elderly & Community Care, Valletta, Malta
| | - S. Ducarroz
- International Agency for Research on Cancer, Lyon, France
| | - H. Erfkamp
- University of Applied Sciences FH Joanneum, Graz, Austria
| | - J. A. Espinàs
- Catalan Cancer Strategy, L’Hospitalet de Llobregat, Spain
| | - J. Faivre
- Digestive Cancer Registry of Burgundy, INSERM U866, University and CHU, Dijon, France
| | - L. Faulds Wood
- Lynn’s Bowel Cancer Campaign, Twickenham, United Kingdom
| | - A. Flugelman
- National Israeli Breast and Colorectal Cancer Detection, Haifa, Israel
| | - S. Frkovic-Grazio
- Department of Gynecological Pathology and Cytology, University Medical Center Ljubljana, Slovenia
| | - B. Geller
- University of Vermont, Burlington, Vermont, United States of America
| | - L. Giordano
- CPO Piemonte, AO Città della Salute e della Scienza di Torino, Turin Italy
| | - G. Grazzini
- Cancer Prevention and Research Institute (ISPO), Florence, Italy
| | - J. Green
- University of Oxford, Oxford, United Kingdom
| | | | - C. Herrmann
- Formerly International Agency for Research on Cancer, Lyon, France,Cancer League of Eastern Switzerland, St. Gallen, Switzerland
| | - P. Hewitson
- University of Oxford, Oxford, United Kingdom
| | - G. Hoff
- Cancer Registry of Norway, Oslo, Norway,Telemark Hospital, Skien, Norway
| | - I. Holten
- Danish Cancer Society, Copenhagen, Denmark
| | - R. Jover
- Hospital General Universitario de Alicante, Alicante, Spain
| | - M. F. Kaminski
- Maria Sklodowska-Curie Memorial Cancer Centre and Medical Centre for Postgraduate Education, Warsaw, Poland
| | | | | | - R. Lambert
- International Agency for Research on Cancer, Lyon, France
| | - G. Launoy
- U1086 INSERM – UCBN, CHU Caen, France
| | - W. Lee
- The Catholic University of Korea College of Medicine, Seoul, Republic of Korea
| | | | - M. Leja
- University of Latvia, Riga, Latvia
| | - D. Lieberman
- Oregon Health & Science University, Portland, Oregon, United States of America
| | - T. Lignini
- International Agency for Research on Cancer, Lyon, France
| | - E. Lucas
- International Agency for Research on Cancer, Lyon, France
| | - E. Lynge
- University of Copenhagen, Copenhagen, Denmark
| | - S. Mádai
- MaMMa Healthcare Institute, Budapest, Hungary
| | - J. Marinho
- Health Administration Central Region Portugal, Aveiro, Portugal
| | | | - G. Minoli
- Gastroenterology Unit, Valduce Hospital, Como, Italy
| | - C. Monk
- GlaxoSmithKline Pharma Europe, London, United Kingdom
| | - A. Morais
- Regional Health Administration, Coimbra, Portugal
| | - R. Muwonge
- International Agency for Research on Cancer, Lyon, France
| | - M. Nadel
- Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America
| | - L. Neamtiu
- Prof. Dr Ion Chiricuţă, Cluj-Napoca, Romania
| | - M. Peris Tuser
- Catalan Institute of Oncology, L’Hospitalet de Llobregat, Spain
| | - M. Pignone
- University of North Carolina, Chapel Hill, North Carolina, United States of America
| | - C. Pox
- Ruhr Universität, Bochum, Germany
| | - M. Primic-Zakelj
- Epidemiology and Cancer Registry, Institute of Oncology Ljubljana, Slovenia
| | - J. Psaila
- National Health Screening Services, Ministry of Health, Elderly & Community Care, Valletta, Malta
| | - L. Rabeneck
- University of Toronto and Cancer Care Ontario, Toronto, Canada
| | - D. Ransohoff
- University of North Carolina, Chapel Hill, North Carolina, United States of America
| | - M. Rasmussen
- Bispebjerg University Hospital, Copenhagen, Denmark
| | - J. Regula
- Maria Sklodowska-Curie Memorial Cancer Centre and Medical Centre for Postgraduate Education, Warsaw, Poland
| | - J. Ren
- Formerly International Agency for Research on Cancer, Lyon, France
| | - G. Rennert
- National Israeli Breast and Colorectal Cancer Detection, Haifa, Israel
| | - J. Rey
- Institut Arnault Tzanck, St Laurent du Var, France
| | | | - M. Risio
- Institute for Cancer Research and Treatment, Candiolo-Torino, Italy
| | - V. Rodrigues
- Faculdade de Medicina – Universidade de Coimbra, Coimbra, Portugal
| | - H. Saito
- National Cancer Centre, Tokyo, Japan
| | - C. Sauvaget
- International Agency for Research on Cancer, Lyon, France
| | | | | | - C. Senore
- CPO Piemonte, AO Città della Salute e della Scienza di Torino, Turin Italy
| | - M. Siddiqi
- Cancer Foundation of India, Kolkata, India
| | - D. Sighoko
- Formerly International Agency for Research on Cancer, Lyon, France,The University of Chicago, Department of Medicine, Hematology–Oncology Section, Center for Clinical Cancer Genetics, Global Health, Chicago, United States of America
| | - R. Smith
- American Cancer Society, Atlanta, Georgia, United States of America
| | - S. Smith
- University Hospitals Coventry & Warwickshire NHS Trust, Coventry, United Kingdom
| | - S. Suchanek
- Charles University and Military University Hospital, Prague, Czech Republic
| | - E. Suonio
- International Agency for Research on Cancer, Lyon, France
| | - W. Tong
- Chinese Academy of Medical Sciences, Beijing, China
| | - S. Törnberg
- Department of Cancer Screening, Stockholm Gotland Regional Cancer Centre, Stockholm, Sweden
| | | | - L. Vignatelli
- Agenzia Sanitaria e Sociale Regionale–Regione Emilia-Romagna, Bologna, Italy
| | - P. Villain
- University of Oxford, Oxford, United Kingdom
| | - L. Voti
- Formerly International Agency for Research on Cancer, Lyon, France,University of Miami, Miami, Florida, United States of America
| | | | - J. Watson
- University of Oxford, Oxford, United Kingdom
| | - S. Winawer
- Memorial Sloan–Kettering Cancer Center, New York, United States of America
| | - G. Young
- Gastrointestinal Services, Flinders University, Adelaide, Australia
| | - V. Zaksas
- State Patient Fund, Vilnius, Lithuania
| | - M. Zappa
- Cancer Prevention and Research Institute (ISPO), Florence, Italy
| | - R. Valori
- NHS Endoscopy, Leicester, United Kingdom
| |
Collapse
|
74
|
Zucali PA, Di Tommaso L, Petrini I, Battista S, Lee HS, Merino M, Lorenzi E, Voulaz E, De Vincenzo F, Simonelli M, Roncalli M, Giordano L, Alloisio M, Santoro A, Giaccone G. Reproducibility of the WHO classification of thymomas: practical implications. Lung Cancer 2012; 79:236-41. [PMID: 23279873 DOI: 10.1016/j.lungcan.2012.11.015] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2012] [Revised: 11/16/2012] [Accepted: 11/19/2012] [Indexed: 10/27/2022]
Abstract
BACKGROUND The WHO-classification was shown to be an independent prognostic marker in some but not all retrospective studies possibly due to lack of reproducibility. We investigated the reproducibility of the WHO-classification and its prognostic implication using a large series of resected thymomas. METHODS Four independent pathologists histologically classified a surgical series of 129 thymic tumors in a blinded fashion. Fleiss' kappa-coefficient was used to assess the pathologists' overall agreement, and Cohen-Kappa to assess the agreement between two observers. Disease-related-survival (DRS) and progression-free-survival (PFS) curves were generated by Kaplan-Meier method and compared by log-rank test. RESULTS In 63/129 (48.8%) cases there was a complete agreement; in 43/129 (33.3%) cases 3/4 pathological diagnoses were identical; in 15/129 (11.6%) cases the diagnoses were identical by pair; in 8/129 (6.2%) cases three different pathological diagnoses were on record. The Kappa-correlation coefficient was only moderate (0.53). A following web review carried out on the 23 cases with at least two different diagnoses reached a complete consensus. The histotype showed a statistically significant impact on PFS and DRS in the classification provided by only two pathologists. CONCLUSIONS In this study, the agreement on WHO classification of thymomas was only moderate and this impacted on patients management. Web consensus conference on the diagnosis, more stringent diagnostic criteria or the adoption of referral diagnostic centres may substantially reduce discrepancies.
Collapse
Affiliation(s)
- P A Zucali
- Humanitas Cancer Center, Via Manzoni 56, Rozzano, Milan, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
75
|
Agostinelli S, Traverso M, Accorsi P, Beccaria F, Belcastro V, Capovilla G, Cappanera S, Coppola A, Dalla Bernardina B, Darra F, Ferretti M, Elia M, Galeone D, Giordano L, Gobbi G, Nicita F, Parisi P, Pezzella M, Spalice A, Striano S, Tozzi E, Vignoli A, Minetti C, Zara F, Striano P, Verrotti A. Early-onset absence epilepsy:SLC2A1gene analysis and treatment evolution. Eur J Neurol 2012; 20:856-9. [DOI: 10.1111/j.1468-1331.2012.03871.x] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2012] [Accepted: 08/16/2012] [Indexed: 11/30/2022]
Affiliation(s)
- S. Agostinelli
- Department of Pediatrics; University of Chieti; Chieti; Italy
| | - M. Traverso
- Pediatric Neurology and Muscular Diseases Unit; ‘G. Gaslini’ Institute; Genoa; Italy
| | - P. Accorsi
- Child Neuropsychiatry; Spedali Civili; Brescia; Italy
| | - F. Beccaria
- Department of Child Neuropsychiatry; C. Poma Hospital; Mantova; Italy
| | - V. Belcastro
- Department of Neuroscience; Sant'Anna Hospital; Como; Italy
| | - G. Capovilla
- Department of Child Neuropsychiatry; C. Poma Hospital; Mantova; Italy
| | - S. Cappanera
- Department of Pediatric Neurology; Ospedali Riuniti; Ancona; Italy
| | - A. Coppola
- Department of Neurological Sciences; Federico II University; Naples; Italy
| | | | - F. Darra
- Unit of Child Neuropsychiatry; University of Verona; Verona; Italy
| | - M. Ferretti
- Pediatric Neurology and Muscular Diseases Unit; ‘G. Gaslini’ Institute; Genoa; Italy
| | - M. Elia
- Department of Neurology; Oasi Institute for Research on Mental Retardation and Brain Aging; Troina; Italy
| | - D. Galeone
- Child Neurology; Children's Hospital Giovanni XXIII; Bari; Italy
| | - L. Giordano
- Child Neuropsychiatry; Spedali Civili; Brescia; Italy
| | - G. Gobbi
- Department of Child Neuropsychiatry; Maggiore Hospital; Bologna; Italy
| | - F. Nicita
- Department of Pediatrics; University of Rome ‘La Sapienza’; Rome; Italy
| | - P. Parisi
- Child Neurology; II Faculty of Medicine; ‘La Sapienza’ University; Rome; Italy
| | - M. Pezzella
- Pediatric Neurology and Muscular Diseases Unit; ‘G. Gaslini’ Institute; Genoa; Italy
| | - A. Spalice
- Child Neurology Unit; Department of Pediatrics; ‘La Sapienza’ University; Rome; Italy
| | - S. Striano
- Department of Neurological Sciences; Federico II University; Naples; Italy
| | - E. Tozzi
- Department of Child Neuropsychiatry; University of L'Aquila; L'Aquila; Italy
| | - A. Vignoli
- Epilepsy Center; University of Milan; Milan; Italy
| | - C. Minetti
- Pediatric Neurology and Muscular Diseases Unit; ‘G. Gaslini’ Institute; Genoa; Italy
| | - F. Zara
- Pediatric Neurology and Muscular Diseases Unit; ‘G. Gaslini’ Institute; Genoa; Italy
| | - P. Striano
- Pediatric Neurology and Muscular Diseases Unit; ‘G. Gaslini’ Institute; Genoa; Italy
| | - A. Verrotti
- Department of Pediatrics; University of Chieti; Chieti; Italy
| | | |
Collapse
|
76
|
De Sanctis R, Bertuzzi A, Magnoni P, Giordano L, Gasco M, Lutman R, Santoro A. Superiority of Choi vs Recist Criteria in Evaluating Outcome of Advanced Soft Tissue Sarcoma (STS) Patients Treated with Sorafenib. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)34052-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022] Open
|
77
|
Austoker J, Giordano L, Hewitson P, Villain P. European guidelines for quality assurance in colorectal cancer screening and diagnosis. First Edition--Communication. Endoscopy 2012; 44 Suppl 3:SE164-85. [PMID: 23012120 DOI: 10.1055/s-0032-1309809] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
Multidisciplinary, evidence-based guidelines for quality assurance in colorectal cancer screening and diagnosis have been developed by experts in a project coordinated by the International Agency for Research on Cancer. The full guideline document covers the entire process of population-based screening. It consists of 10 chapters and over 250 recommendations, graded according to the strength of the recommendation and the supporting evidence. The 450-page guidelines and the extensive evidence base have been published by the European Commission. The chapter on communication includes 35 graded recommendations. The content of the chapter is presented here to promote international discussion and collaboration by making the principles and standards recommended in the new EU Guidelines known to a wider professional and scientific community. Following these recommendations has the potential to enhance the control of colorectal cancer through improvement in the quality and effectiveness of screening programmes and services.
Collapse
Affiliation(s)
- J Austoker
- University of Oxford, Oxford, United Kingdom
| | | | | | | | | |
Collapse
|
78
|
Giarratana F, Ziino G, Signorino D, Giordano L, Giuffrida A. EFFECT OF SIDEROPHORES AGAINST E. COLI O157:H7. Ital J Food Saf 2012. [DOI: 10.4081/ijfs.2012.4.57] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
|
79
|
Díaz SA, Giordano L, Jovin TM, Jares-Erijman EA. Modulation of a photoswitchable dual-color quantum dot containing a photochromic FRET acceptor and an internal standard. Nano Lett 2012; 12:3537-3544. [PMID: 22663176 DOI: 10.1021/nl301093s] [Citation(s) in RCA: 63] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Abstract
Photoswitchable semiconductor nanoparticles, quantum dots (QDs), couple the advantages of conventional QDs with the ability to reversibly modulate the QD emission, thereby improving signal detection by rejection of background signals. Using a simple coating methodology with polymers incorporating a diheteroarylethene photochromic FRET acceptor as well as a spectrally distinct organic fluorophore, photoswitchable QDs were prepared that are small, biocompatible, and feature ratiometric dual emission. With programmed irradiation, the fluorescence intensity ratio can be modified by up to ∼100%.
Collapse
Affiliation(s)
- Sebastián A Díaz
- Departamento de Química Orgánica, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, CIHIDECAR, CONICET, 1428 Buenos Aires, Argentina
| | | | | | | |
Collapse
|
80
|
Manchester J, Bassani DM, Duprey JLHA, Giordano L, Vyle JS, Zhao ZY, Tucker JHR. Photocontrolled binding and binding-controlled photochromism within anthracene-modified DNA. J Am Chem Soc 2012; 134:10791-4. [PMID: 22694485 PMCID: PMC3614019 DOI: 10.1021/ja304205m] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Modified DNA strands undergo a reversible light-induced reaction involving the intramolecular photodimerization of two appended anthracene tags. The photodimers exhibit markedly different binding behavior toward a complementary strand that depends on the number of bases between the modified positions. By preforming the duplex, photochromism can be suppressed, illustrating dual-mode gated behavior.
Collapse
Affiliation(s)
- Jack Manchester
- School of Chemistry, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK
| | | | | | | | | | | | | |
Collapse
|
81
|
Abstract
Introduction of the dialkylaminophenyl group in position 7 of 3-hydroxychromone changes the orientation of the excited-state dipole moment and leads to superior solvatochromic properties (>170 nm emission shift in aprotic media). The excited-state intramolecular proton-transfer (ESIPT) reaction of 7-aryl-3-hydroxychromones is almost completely inhibited in most solvents. Methylation of the 3-OH abolishes ESIPT completely and also leads to improved photostability. The probes exhibit a ∼100-fold increase in fluorescence intensity and large Stokes shifts upon binding to membranes, reflecting differences in membrane phase and charge by a >40 nm spread in the emission band position.
Collapse
Affiliation(s)
- Luciana Giordano
- †Laboratory for Cellular Dynamics, Max Planck Institute for Biophysical Chemistry, Am Faßberg 11, Göttingen, Germany
| | - Volodymyr V Shvadchak
- †Laboratory for Cellular Dynamics, Max Planck Institute for Biophysical Chemistry, Am Faßberg 11, Göttingen, Germany
| | - Jonathan A Fauerbach
- ‡Departamento de Química Orgánica, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Buenos Aires, Argentina
| | - Elizabeth A Jares-Erijman
- ‡Departamento de Química Orgánica, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Buenos Aires, Argentina
| | - Thomas M Jovin
- †Laboratory for Cellular Dynamics, Max Planck Institute for Biophysical Chemistry, Am Faßberg 11, Göttingen, Germany
| |
Collapse
|
82
|
De Leonibus C, Lembo C, Giliberti P, Rojo S, Foglia MC, Giordano L, Fratta A. [A case of neonatal lupus syndrome and congenital atrioventricular block associated with maternal antibodies antiRo/SS-A]. Minerva Pediatr 2012; 64:251-256. [PMID: 22495199] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Abstract
The neonatal lupus erythematosus syndrome (LEN) is a disease due to the transplacental passage of maternal antiextractable nuclear antigens (ENA) antibodies, particularly anti-Ro/SS-A and anti-La/SS-B. The disease affects neonates born from mothers with autoimmune diseases. It is characterized by erythematous annular polycylic skin lesions, slightly scaling with prevalent face localization, hematologic and liver diseases and only in 2% of cases with extracutaneous lesions including complete atrioventricular block. The Authors describe a case of LEN characterized by isolated atrioventricular block at birth and endocardial fibroelastosis without skin lesions in a preterm infant female. She was born from asymptomatic, ANA (Anti-Nuclear Antibodies) and ENA (anti-Extractable Nuclear Antigen) positive mother, with a previous miscarriage at the 5th week of gestation.
Collapse
MESH Headings
- Adult
- Antibodies, Antinuclear/blood
- Atrioventricular Block/congenital
- Atrioventricular Block/immunology
- Atrioventricular Block/therapy
- Biomarkers/blood
- Endocardial Fibroelastosis/congenital
- Fatal Outcome
- Female
- Humans
- Hydrothorax/etiology
- Hydrothorax/surgery
- Immunologic Factors/blood
- Infant, Newborn
- Infant, Premature
- Infant, Premature, Diseases
- Lupus Erythematosus, Systemic/blood
- Lupus Erythematosus, Systemic/complications
- Lupus Erythematosus, Systemic/congenital
- Lupus Erythematosus, Systemic/immunology
- Lupus Erythematosus, Systemic/therapy
- Maternal-Fetal Exchange/immunology
- Mothers
- Pregnancy
- Risk Factors
Collapse
Affiliation(s)
- C De Leonibus
- Divisione di Neonatologia e Terapia Intensiva Neonatale, V. Monaldi, Napoli, Italia
| | | | | | | | | | | | | |
Collapse
|
83
|
Tonini MC, Giordano L, Atzeni L, Bogliun G, Perri G, Saracco MG, Tombini M, Torelli P, Turazzini M, Vernieri F, Aguggia M, Bussone G, Beghi E. Primary headache and epilepsy: a multicenter cross-sectional study. Epilepsy Behav 2012; 23:342-7. [PMID: 22377332 DOI: 10.1016/j.yebeh.2012.01.017] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/08/2011] [Revised: 01/18/2012] [Accepted: 01/22/2012] [Indexed: 11/17/2022]
Abstract
The prevalence and characteristics of interictal headache, epilepsy and headache/epilepsy comorbidity were assessed in 858 women and 309 men aged 18-81 years from headache and epilepsy centers in Italy. The research hypothesis was that comorbidity among patients with either disorder would be expected to be higher than in the general population. Interictal headache was diagnosed in 675 cases (migraine 482; tension-type headache 168; other types 25), epilepsy in 336 (partial 171; generalized 165) and comorbidity in 156 (1.6% from headache centers; 30.0% from epilepsy centers). Patients with epilepsy, headache and comorbidity differed in a number of demographic and clinical aspects. However, for both headache and epilepsy, a family history of the same clinical condition was equally prevalent in patients with and without comorbidity. These findings do not support the purported association between headache and epilepsy.
Collapse
Affiliation(s)
- M C Tonini
- Department of Neurology, Headache Center, G. Salvini Hospital, Garbagnate Mse (MI), Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
84
|
Gullo G, Bettio D, Zuradelli M, Masci G, Giordano L, Bareggi C, Salvini P, Runza L, Santoro A. P1-12-22: Impact on Survival of the Level of HER2/neu Gene Amplification in Patients with HER2−Positive (HER2+) Advanced Breast Cancer (AdvBrCa) Treated with Trastuzumab (H). Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-p1-12-22] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background The level of HER2/neu (HER2) amplification, defined as HER2/centromeric region of chromosome 17 (CEP17) ratio at dual-color fluorescent in-situ hybridization (FISH) test presents wide variations in clinical practice but its clinical significance is still undefined. We designed this retrospective study to investigate the correlations between level of HER2 amplification in primary (T) and/or metastases (M) and outcome in a cohort of HER2+ AdvBrCa pts treated with a H-containing therapy.
Methods Retrospective multicentric study designed according to REporting recommendations for tumor MARKer prognostic studies (REMARK). To be included pts must have all the following: metastatic or locally advanced (not amenable of curative surgery) BrCa, HER2+ tumour defined as score 3+ at immunohistochemistry or FISH positive, treatment with a H-containing regimen (no H in neo- or adjuvant setting was allowed), at least one tumour sample from T and/or M available, measurable or evaluable disease, adequate follow up (FU) information.Outcome parameters included event-free survival (EFS) and overall survival (OS). All FISH tests were prospectively performed in a central laboratory of cytogenetic specifically for this study and in accordance with the international guidelines on FISH testing.
Results Ninety-one females were identified and 63 included in the final analysis. Forty-seven pts had one specimen available from T or M, 16 pts had two specimens from either T and a corresponding M. All M samples were obtained before treatment with H. Median FU time is 19.2 months (range 1.2−94.6). In 11 out of 16 cases (69%) with two tumour specimens HER2/CEP17 ratio was higher in M than in T with a statistically significant difference in the median HER2/CEP17 ratio between T (8.3, range: 3.1−18.4) and the corresponding M (10.9, range: 4.6−20.8) (p=0.004). The incremental gain in HER2/CEP17 ratio was associated with significantly shorter OS after trastuzumab-based therapy (p=0.023). A trend towards a correlation between increase in level of HER2 amplification assessed in M and shorter EFS and OS was observed. No statistically significant correlation was found between level of HER2 amplification assessed in T and EFS and OS.
Conclusions Level of HER2 amplification reported as HER2/CEP17 ratio is a dynamic parameter in HER2+ AdvBrCa as it increases from T to the matched M in a significant proportion of pts. The gain in HER2 gene copies may represent a prognostic factor for shorter OS when pts with HER2+ AdvBrCa are treated with a H-based therapy. Further studies on the level of HER2 amplification in BrCa metastases are strongly warranted to better understand the biology of HER2−positive breast cancer and to better identify patients with a poorer prognosis after treatment with H.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P1-12-22.
Collapse
Affiliation(s)
- G Gullo
- 1St Vincent's University Hospital, Dublin, Ireland; Istituto Clinico Humanitas, Rozzano, MILano, Italy; Humanitas Cancer Centre, Rozzano, MILano, Italy; Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milano, Italy; Cliniche Humanitas Gavazzeni, Bergamo, Italy
| | - D Bettio
- 1St Vincent's University Hospital, Dublin, Ireland; Istituto Clinico Humanitas, Rozzano, MILano, Italy; Humanitas Cancer Centre, Rozzano, MILano, Italy; Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milano, Italy; Cliniche Humanitas Gavazzeni, Bergamo, Italy
| | - M Zuradelli
- 1St Vincent's University Hospital, Dublin, Ireland; Istituto Clinico Humanitas, Rozzano, MILano, Italy; Humanitas Cancer Centre, Rozzano, MILano, Italy; Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milano, Italy; Cliniche Humanitas Gavazzeni, Bergamo, Italy
| | - G Masci
- 1St Vincent's University Hospital, Dublin, Ireland; Istituto Clinico Humanitas, Rozzano, MILano, Italy; Humanitas Cancer Centre, Rozzano, MILano, Italy; Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milano, Italy; Cliniche Humanitas Gavazzeni, Bergamo, Italy
| | - L Giordano
- 1St Vincent's University Hospital, Dublin, Ireland; Istituto Clinico Humanitas, Rozzano, MILano, Italy; Humanitas Cancer Centre, Rozzano, MILano, Italy; Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milano, Italy; Cliniche Humanitas Gavazzeni, Bergamo, Italy
| | - C Bareggi
- 1St Vincent's University Hospital, Dublin, Ireland; Istituto Clinico Humanitas, Rozzano, MILano, Italy; Humanitas Cancer Centre, Rozzano, MILano, Italy; Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milano, Italy; Cliniche Humanitas Gavazzeni, Bergamo, Italy
| | - P Salvini
- 1St Vincent's University Hospital, Dublin, Ireland; Istituto Clinico Humanitas, Rozzano, MILano, Italy; Humanitas Cancer Centre, Rozzano, MILano, Italy; Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milano, Italy; Cliniche Humanitas Gavazzeni, Bergamo, Italy
| | - L Runza
- 1St Vincent's University Hospital, Dublin, Ireland; Istituto Clinico Humanitas, Rozzano, MILano, Italy; Humanitas Cancer Centre, Rozzano, MILano, Italy; Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milano, Italy; Cliniche Humanitas Gavazzeni, Bergamo, Italy
| | - A Santoro
- 1St Vincent's University Hospital, Dublin, Ireland; Istituto Clinico Humanitas, Rozzano, MILano, Italy; Humanitas Cancer Centre, Rozzano, MILano, Italy; Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milano, Italy; Cliniche Humanitas Gavazzeni, Bergamo, Italy
| |
Collapse
|
85
|
Koppe T, Cardella A, Missal B, Hein B, Krause R, Jenzsch H, Reich J, Leher F, Binni A, Segl J, Camin R, Giordano L, Langone S, Ridzewski J, Corniani G. Overview of main-mechanical-components and critical manufacturing aspects of the Wendelstein 7-X cryostat. Fusion Engineering and Design 2011. [DOI: 10.1016/j.fusengdes.2011.05.010] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
86
|
Zucali PA, Simonelli M, Michetti G, Tiseo M, Ceresoli GL, Collovà E, Follador A, Lo Dico M, Moretti A, De Vincenzo F, Lorenzi E, Perrino M, Giordano L, Farina G, Santoro A, Garassino M. Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey. Lung Cancer 2011; 75:360-7. [PMID: 21937142 DOI: 10.1016/j.lungcan.2011.08.011] [Citation(s) in RCA: 76] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2011] [Revised: 08/19/2011] [Accepted: 08/20/2011] [Indexed: 12/30/2022]
Abstract
The pemetrexed-cisplatin chemotherapy is standard of care in first-line (FL) treatment of malignant pleural mesothelioma (MPM). The second-line (SL) chemotherapy is considered, but the optimal treatment has not been defined yet. The aim of this study was to evaluate the clinical outcomes of SL-therapy in a series of MPM-patients included in a retrospective multicenter database. Clinical records of MPM-patients who received SL-treatment from 1996 to 2008 were reviewed. Study endpoints were response, overall-survival (OS), and progression-free-survival (PFS) for SL, stratified for patient characteristics, FL-outcomes, and type of SL. Out of 423 patients, 181 with full clinical data were identified. Patients' characteristics: median-age 64 years (range: 36-85); male gender 115 (63.5%); good EORTC-score 109 (60.2%); epithelial histology 135 (74.6%). After FL, 147 (81.2%) patients achieved disease-control (DC) and 45 had a time-to-progression≥12 months (TTP≥12). After SL, 95 patients (52.6%) achieved DC (21 response; 74 stable-disease); median PFS and OS were 4.3 and 8.7 months, respectively. According to multivariate analysis, DC after SL-therapy was significantly related to pemetrexed-based treatment (OR: 2.46; p=0.017) and FL-TTP≥12 (OR: 3.50; p=0.006). PFS was related to younger age (<65 years) (HR: 0.70; p=0.045), ECOG-PS0 (HR: 0.67; p=0.022), and FL-TTP≥12 (HR: 0.45; p<0.001). OS was significantly related to ECOG-PS0 (HR: 0.43; p<0.001) and to FL-TTP≥12 (HR: 0.54; p=0.005). In pemetrexed pre-treated patients, re-treatment with a pemetrexed/platinum combination significantly reduced the risk-of-death than pemetrexed alone (HR: 0.11; p<0.001). In conclusion, SL-chemotherapy seems to be active in MPM-patients, particularly in younger patients with ECOG-PS0 and prolonged TTP after FL-pemetrexed-based chemotherapy. In selected patients, re-challenge with pemetrexed-based regimens, preferentially associated with platinum-compound, appears to be an option for SL-setting. Considering the important limitations of this study, due to retrospective nature and the possible selection bias, prospective clinical trials are warranted to clarify these issues.
Collapse
Affiliation(s)
- P A Zucali
- Department of Oncology, Humanitas Cancer Center, Rozzano, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
87
|
Striano P, Paravidino R, Sicca F, Chiurazzi P, Gimelli S, Coppola A, Robbiano A, Traverso M, Pintaudi M, Giovannini S, Operto F, Vigliano P, Granata T, Coppola G, Romeo A, Specchio N, Giordano L, Osborne LR, Gimelli G, Minetti C, Zara F. West syndrome associated with 14q12 duplications harboring FOXG1. Neurology 2011; 76:1600-2. [PMID: 21536641 DOI: 10.1212/wnl.0b013e3182194bbf] [Citation(s) in RCA: 46] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Affiliation(s)
- P Striano
- Muscular and Neurodegenerative Diseases Unit, Institute G. Gaslini, University of Genova, Genova, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
88
|
Toschi L, Colombo P, Soldani C, Giordano L, Finocchiaro G, Siracusano L, Gianoncelli L, Incarbone M, Destro A, Alloisio M, Terracciano L, Varella-Garcia M, Cappuzzo F, Roncalli M, Viola A, Santoro A. Prognostic role of nitrotyrosines in surgically resected non-small cell lung cancer (NSCLC). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.7064] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
89
|
Simonelli M, Zucali PA, De Sanctis R, Lorenzi E, De Vincenzo F, Rimassa L, Tronconi MC, Personeni N, Masci G, Zuradelli M, Perrino M, Bertossi M, Giordano L, Santoro A. Phase I, pharmacokinetic (PK), pharmacodynamic (PD) study of lapatinib (L) in combination with sorafenib (S) in patients with advanced refractory solid tumors. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.2521] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
90
|
Pressiani T, Rimassa L, Boni C, Labianca R, Fagiuoli S, Ardizzoni A, Foa P, Cortesi E, Porta C, Artioli F, Latini L, Carnaghi C, Lutman RF, Torzilli G, Tommasini M, Ceriani R, Covini G, Giordano L, Locopo N, Santoro A. Phase II randomized trial on dose-escalated sorafenib (S) versus best supportive care (BSC) in patients with advanced hepatocellular carcinoma (HCC) with disease progression on prior S treatment. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.4115] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
91
|
Díaz SA, Menéndez GO, Etchehon MH, Giordano L, Jovin TM, Jares-Erijman EA. Photoswitchable water-soluble quantum dots: pcFRET based on amphiphilic photochromic polymer coating. ACS Nano 2011; 5:2795-2805. [PMID: 21375335 DOI: 10.1021/nn103243c] [Citation(s) in RCA: 62] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
A novel surface architecture was developed to generate biocompatible and stable photoswitchable quantum dots (psQDs). Photochromic diheteroarylethenes, which undergo thermally stable photoconversions between two forms with different spectral properties in organic solvents, were covalently linked to an amphiphilic polymer that self-assembles with the lipophilic chains surrounding commercial hydrophobic core-shell CdSe/ZnS QDs. This strategy creates a small (∼7 nm diameter) nanoparticle (NP) that is soluble in aqueous medium. The NP retains and even enhances the desirable properties of the original QD (broad excitation, narrow emission, photostability), but the brightness of its emission can be tailored by light. The modulation of emission monitored by steady-state and time-resolved fluorescence was 35-40%. The psQDs exhibit unprecedented photostability and fatigue resistance over at least 16 cycles of photoconversion.
Collapse
Affiliation(s)
- Sebastián A Díaz
- Departamento de Química Orgánica, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, CIHIDECAR, CONICET, 1428 Buenos Aires, Argentina
| | | | | | | | | | | |
Collapse
|
92
|
Roberti MJ, Giordano L, Jovin TM, Jares-Erijman EA. Corrigendum: FRET Imaging by kt/kf. Chemphyschem 2011. [DOI: 10.1002/cphc.201190031] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
93
|
Affiliation(s)
- M. Julia Roberti
- Departamento de Química Orgánica, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, CIHIDECAR, CONICET, Ciudad Universitaria, Pabellón II/Piso 3, 1428 Buenos Aires (Argentina), Fax: (+54) 11‐4576‐3346
| | - Luciana Giordano
- Laboratory of Cellular Dynamics, Max Planck Institute for Biophysical Chemistry am Fassberg 11, 37077 Göttingen (Germany), Fax: (+49) 551‐2011467
| | - Thomas M. Jovin
- Laboratory of Cellular Dynamics, Max Planck Institute for Biophysical Chemistry am Fassberg 11, 37077 Göttingen (Germany), Fax: (+49) 551‐2011467
| | - Elizabeth A. Jares‐Erijman
- Departamento de Química Orgánica, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, CIHIDECAR, CONICET, Ciudad Universitaria, Pabellón II/Piso 3, 1428 Buenos Aires (Argentina), Fax: (+54) 11‐4576‐3346
| |
Collapse
|
94
|
Giordano L, Hoang CT, Shipman M, Tucker JHR, Walsh TR. Aziridine Scaffolds for the Detection and Quantification of Hydrogen-Bonding Interactions through Transition-State Stabilization. Angew Chem Int Ed Engl 2011. [DOI: 10.1002/ange.201005580] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
95
|
Giordano L, Hoang CT, Shipman M, Tucker JHR, Walsh TR. Aziridine scaffolds for the detection and quantification of hydrogen-bonding interactions through transition-state stabilization. Angew Chem Int Ed Engl 2011; 50:741-4. [PMID: 21226167 DOI: 10.1002/anie.201005580] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2010] [Revised: 10/26/2010] [Indexed: 11/05/2022]
Affiliation(s)
- Luciana Giordano
- School of Chemistry, University of Birmingham, Edgbaston, Birmingham, B15 2TT UK
| | | | | | | | | |
Collapse
|
96
|
Giordano L, Sartori S, Russo S, Accorsi P, Galli J, Tiberti A, Bettella E, Marchi M, Vignoli A, Darra F, Murgia A, Bernardina BD. Familial Ohtahara syndrome due to a novel ARX gene mutation. Am J Med Genet A 2010; 152A:3133-7. [DOI: 10.1002/ajmg.a.33701] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
|
97
|
Del Sole A, Chiesa V, Lucignani G, Vignoli A, Giordano L, Lecchi M, Canevini MP. Exploring dopaminergic activity in ring chromosome 20 syndrome: a SPECT study. Q J Nucl Med Mol Imaging 2010; 54:564-569. [PMID: 20927024] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
AIM Several lines of evidence indicate that the dopaminergic system may play a role in the propagation of epileptic seizures and, indeed, DOPA metabolism impairment has recently been demonstrated in PET studies of ring chromosome 20 [r(20)] patients. We conducted a study looking for correlations between r(20) mosaicism, other clinical variables and both pre-synaptic dopamine transporter (DAT) expression and post-synaptic D2 receptor density. METHODS Five patients with r(20) and epilepsy were enrolled in the study. DAT expression and D2 density were measured by single photon emission tomography (SPECT) imaging with 185 MBq of [¹²³I]ioflupane and [¹²³I]IBZM, respectively, on different days. Linear correlations between r(20) mosaicism, clinical variables and binding of [¹²³I]ioflupane or [¹²³I]IBZM were examined. RESULTS A significant correlation between seizure frequency and r(20) mosaicism was detected (r=0.903, P<0.05), along with a negative correlation between r(20) mosaicism and binding of [¹²³I]ioflupane in the putamen and in the caudate nucleus (r=-0.692 and r=-807; P<0.05). Seizure frequency was positively correlated with post-synaptic D2 density (r=0.925, P<0.05). CONCLUSION Striatal neurons are involved in r(20) epilepsy; the relationship found between r(20) mosaicism and DAT expression suggests that drugs acting on the dopaminergic system could have a place in the treatment of this rare form of epilepsy.
Collapse
Affiliation(s)
- A Del Sole
- Department of Biomedical Sciences and Technologies and Center of Molecular and Cellular Imaging (IMAGO), University of Milan, Milan, Italy.
| | | | | | | | | | | | | |
Collapse
|
98
|
Castagna L, Bramanti S, Levis A, Michieli M, Anastasia A, Mazza R, Giordano L, Sarina B, Todisco E, Gregorini A, Santoro A. Pegfilgrastim versus filgrastim after high-dose chemotherapy and autologous peripheral blood stem cell support. Ann Oncol 2010; 21:1482-1485. [DOI: 10.1093/annonc/mdp576] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
99
|
Del Sole A, Chiesa V, Lucignani G, Vignoli A, Giordano L, Lecchi M, Canevini MP. Exploring dopaminergic activity in ring chromosome 20 syndrome: a SPECT study. Q J Nucl Med Mol Imaging 2010:R39102225. [PMID: 20585311] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 05/29/2023]
Abstract
AIM: Several lines of evidence indicate that the dopaminergic system may play a role in the propagation of epileptic seizures and, indeed, DOPA metabolism impairment has recently been demonstrated in PET studies of ring chromosome 20 [r(20)] patients. We conducted a study looking for correlations between r(20) mosaicism, other clinical variables and both pre-synaptic dopamine transporter (DAT) expression and post-synaptic D2 receptor density. METHODS: Five patients with r(20) and epilepsy were enrolled in the study. DAT expression and D2 density were measured by single photon emission tomography (SPECT) imaging with 185 MBq of [123I]ioflupane and [123I]IBZM, respectively, on different days. Linear correlations between r(20) mosaicism, clinical variables and binding of [123I]ioflupane or [123I]IBZM were examined. RESULTS: A significant correlation between seizure frequency and r(20) mosaicism was detected (r=0.903, P<0.05), along with a negative correlation between r(20) mosaicism and binding of [123I]ioflupane in the putamen and in the caudate nucleus (r=-0.692 and r=-807; P<0.05). Seizure frequency was positively correlated with post-synaptic D2 density (r=0.925, P<0.05). CONCLUSION: Striatal neurons are involved in r(20) epilepsy; the relationship found between r(20) mosaicism and DAT expression suggests that drugs acting on the dopaminergic system could have a place in the treatment of this rare form of epilepsy.
Collapse
Affiliation(s)
- A Del Sole
- Department of Biomedical Sciences and Technologies and Center of Molecular and Cellular Imaging (IMAGO), University of Milan, Milan, Italy -
| | | | | | | | | | | | | |
Collapse
|
100
|
Masci G, Di Tommaso L, Del Prato I, Orefice S, Rubino A, Gullo G, Zuradelli M, Sacco R, Alloisio M, Eboli M, Incarbone M, Giordano L, Roncalli M, Santoro A. Sinusal localization of nodal micrometastases is a prognostic factor in breast cancer. Ann Oncol 2010; 21:1228-1232. [DOI: 10.1093/annonc/mdp453] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open
|